Physician profile
Patrick Hyatt
NPI 1962432005
$5,087.49
in general payments reported to CMS, 2019-2025
30 companies · $597 in 2025
The $597 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $744 · 2020: $332 · 2021: $603 · 2022: $1,025 · 2023: $1,117 · 2024: $670 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.30 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.65 | 2019-2025 | |
| Janssen Biotech, INC. | $499.27 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $489.02 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.34 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $374.02 | 2019-2023 | Entyvio |
| Pfizer INC. | $304.32 | 2019-2025 | |
| Braintree Laboratories, INC. | $179.22 | 2019-2023 | Sutab |
| Genzyme Corporation | $163.60 | 2019-2025 | |
| Medtronic, INC. | $144.45 | 2022 | |
| Nestle Healthcare Nutrition INC. | $143.90 | 2021-2023 | |
| Celgene Corporation | $112.84 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $95.87 | 2024 | Voquezna |
| Qol Medical, LLC | $66.53 | 2023-2024 | Sucraid, Sucraid |
| Olympus America INC. | $65.25 | 2019-2020 | |
| Allergan, INC. | $64.54 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $42.24 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Exelixis INC. | $38.22 | 2019-2022 | |
| Lumendi LLC | $36.00 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $30.37 | 2023 | Givlaari |
| Ardelyx, INC. | $30.01 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $24.80 | 2021 | |
| Aimmune Therapeutics, INC. | $23.58 | 2025 | Zenpep |
| Organon LLC | $21.04 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $21.01 | 2021 | |
| Intercept Pharmaceuticals, INC. | $20.85 | 2023 | Ocaliva |
| Albireo Pharma, INC. | $19.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2021 | |
| Shire North American Group INC | $13.58 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.54 | 2022 | |
| Digestive Care, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.